In 2013 the VIB, the KU Leuven, the UZ Leuven, Janssen and Johnson & Johnson Innovation launched Stellar. This joining of forces has the purpose of making it easier to convert molecular insights in disease processes into new medicines and diagnostics for brain diseases.

Janssen and Johnson & Johnson Innovation are providing financing amounting to five million euros over five years for this project. They will accordingly support academic research projects of VIB, KU Leuven and UZ Leuven. Janssen is very deeply involved with patients with neurodegenerative disorders and people in healthcare taking care of them. 

neurowetenschappen.png

The company believes it is essential to work together with external innovators to arrive at the type of discoveries that can result in the therapies of the future for neurodegenerative disorders. 

Durabilité
Économique

Janssen believes that strong corporate results, correct policies and focused activities pave the way towards economic sustainability. 

Janssen must constantly reinvent itself in order to cope with the structural and economic changes that affect its environment. This is why Janssen is committed to build partnerships within an open innovation model, and to the continuous alignment of its cost-competitiveness by only developing medicines with a high therapeutic added value. 

For Janssen this means specifically: being focused and a leader in research & development, and being efficient and progressive in terms of production with the aim of bringing new therapeutic solutions to patients quicker and at less expense, and implementing a growth strategy to ensure our continued investment in all these areas.